Update from GSK on drisapersen (previously GSK2402968)

GSK will be announcing results from their Phase llb study this week.  We will keep you updated on the news as it comes in.  Here is the note from GSK:

———————————————————————————————————————————————-

To keep you updated on the progress of the drisapersen (previously GSK2402968) clinical development program, as you have requested, I am writing to inform you that the results of the GSK Phase IIb study investigating drisapersen as a potential treatment for DMD boys who have a dystrophin gene mutation amenable to an exon 51 skip will be presented at a scientific conference in the U.S. on the 11^th of April 2013.

The Phase IIb results of the DMD114117 study will be presented for the first time at Cold Spring Harbor, RNA and Oligonucleotide Therapeutics, conference (10-13 April 2013). The  abstract title is “Drisapersen treatment for Duchenne muscular dystrophy—Results of a randomized, double-blind, placebo-controlled clinical trial” and will be presented by Dr John Kraus, GSK.

Should you have any additional questions, please let us know by reply to this communication; specific contact details below.

Best regards

Global Medical Affairs & Patient Relations Team

GSK Rare Diseases